🇺🇸 GENMAB A/SGMAB
Get GENMAB A/S filings on Telegram the moment they are published.
Follow GENMAB A/S on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: Phase 3 LiGeR-HN1 trial results show petosemtamab plus pembrolizumab met primary endpoints, reducing death risk by 50% in first-line PD-L1+ head and neck cancer.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest